C.K. van Kalken

1.3k total citations
17 papers, 1.1k citations indexed

About

C.K. van Kalken is a scholar working on Oncology, Pediatrics, Perinatology and Child Health and Molecular Biology. According to data from OpenAlex, C.K. van Kalken has authored 17 papers receiving a total of 1.1k indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Oncology, 5 papers in Pediatrics, Perinatology and Child Health and 4 papers in Molecular Biology. Recurrent topics in C.K. van Kalken's work include Drug Transport and Resistance Mechanisms (9 papers), Pharmacological Effects and Toxicity Studies (5 papers) and Pancreatic and Hepatic Oncology Research (2 papers). C.K. van Kalken is often cited by papers focused on Drug Transport and Resistance Mechanisms (9 papers), Pharmacological Effects and Toxicity Studies (5 papers) and Pancreatic and Hepatic Oncology Research (2 papers). C.K. van Kalken collaborates with scholars based in Netherlands, Switzerland and Italy. C.K. van Kalken's co-authors include Paul van der Valk, Rik J. Scheper, Herbert M. Pinedo, Elisabeth G.E. de Vries, H J Broxterman, Patricia Kaaijk, Marilyn L. Slovak, Giuseppe Giaccone, G L Scheffer and William S. Dalton and has published in prestigious journals such as The Lancet, Journal of Clinical Oncology and The Journal of Urology.

In The Last Decade

C.K. van Kalken

17 papers receiving 1.1k citations

Peers

Countries citing papers authored by C.K. van Kalken

Since Specialization

Citations

This map shows the geographic impact of C.K. van Kalken's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by C.K. van Kalken with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites C.K. van Kalken more than expected).

Fields of papers citing papers by C.K. van Kalken

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by C.K. van Kalken. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by C.K. van Kalken. The network helps show where C.K. van Kalken may publish in the future.

Co-authorship network of co-authors of C.K. van Kalken

This figure shows the co-authorship network connecting the top 25 collaborators of C.K. van Kalken. A scholar is included among the top collaborators of C.K. van Kalken based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with C.K. van Kalken. C.K. van Kalken is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

17 of 17 papers shown

#	Work	Indexed citations
1	A novel definition and treatment of hyperinflammation in COVID-19 based on purinergic signalling 2021 ·Purinergic Signalling ·Djo Hasan, Atsuko Shono, C.K. van Kalken, Peter J. van der Spek, Eric P. Krenning, Toru Kotani	19
2	Initiation of health-behaviour change among employees participating in a web-based health risk assessment with tailored feedback 2011 ·Journal of Occupational Medicine and Toxicology ·Ersen B Colkesen, (unknown), Niels Peek, (unknown), Roderik A. Kraaijenhagen, C.K. van Kalken, Jan G.P. Tijssen, Ron J.G. Peters	33
3	Phase II Marker Lesion Study With Intravesical Instillation of Apaziquone for Superficial Bladder Cancer: Toxicity and Marker Response 2006 ·The Journal of Urology ·Antoine G. van der Heijden, Paula M.J. Moonen, Erik B. Cornel, H. Vergunst, Theo M. de Reijke, E. Boven, (unknown), Rajiv Puri, C.K. van Kalken, J. Alfred Witjes	56
4	Signal Transduction Modulators for Cancer Therapy: From Promise to Practice? 2003 ·The Oncologist ·Marinus W. Lobbezoo, Giuseppe Giaccone, C.K. van Kalken	4
5	Prognostic relevance of P-glycoprotein expression in breast cancer 1995 ·Annals of Oncology ·S. C. Linn, Giuseppe Giaccone, P. J. van Diest, (unknown), Paul van der Valk, C.K. van Kalken, C.M. Kuiper, Herbert M. Pinedo, J. P. A. Baak	73
6	Complete remission of colorectal cancer: a pitfall in a multidrug resistance reversal trial 1994 ·The Lancet ·SC Linn, Giuseppe Giaccone, C.K. van Kalken, Paul van der Valk, C.M. Kuiper, Herbert M. Pinedo	2
7	Clinical and pharmacologic study of multidrug resistance reversal with vinblastine and bepridil. 1994 ·Journal of Clinical Oncology ·S. C. Linn, C.K. van Kalken, Olaf van Tellingen, Paul van der Valk, C.J. van Groeningen, Catharina M. Kuiper, Herbert M. Pinedo, Giuseppe Giaccone	32
8	Overexpression of a M(r) 110,000 vesicular protein in non-P-glycoprotein-mediated multidrug resistance. 1993 ·PubMed ·Rik J. Scheper, H J Broxterman, G L Scheffer, Patricia Kaaijk, William S. Dalton, (unknown), C.K. van Kalken, Marilyn L. Slovak, Elisabeth G.E. de Vries, Paul van der Valk	433
9	Multidrug resistance gene (P-glycoprotein) expression in the human fetus. 1992 ·PubMed ·C.K. van Kalken, Giuseppe Giaccone, Paul van der Valk, C.M. Kuiper, (unknown), Anneke A. Bosma, Rik J. Scheper, Coby Meijer, H. M. Pinedo	106
10	Bepridil in combination with anthracyclines in the attempt to reverse anthracycline-resistance in cancer patients 1991 ·European Journal of Cancer ·C.K. van Kalken, Jacobus J. M. van der Hoeven, J. de Jong, Giuseppe Giaccone, G.J. Schuurhuis, Paul A. Maessen, (unknown), (unknown), Herbert M. Pinedo	14
11	Differentiation dependent expression of P-glycoprotein in the normal and neoplastic human kidney 1991 ·Annals of Oncology ·C.K. van Kalken, P. van der Valk, (unknown), Rob Pieters, HJ Broxterman, C.M. Kuiper, (unknown), A. Veerman, C. J. L. M. Meyer, Rik J. Scheper, H. M. Pinedo	34
12	AACR Special Conference In Cancer Research Membrane transport in multidrug resistance, development, and disease 1991 ·Annals of Oncology ·Maurizio D’Incalci, Henricus J. Broxterman, C.K. van Kalken	9
13	Multidrug resistance from the clinical point of view 1991 ·European Journal of Cancer and Clinical Oncology ·C.K. van Kalken, Herbert M. Pinedo, Giuseppe Giaccone	39
14	Bepridil in combination with anthracyclines to reverse anthracycline resistance in cancer patients 1991 ·European Journal of Cancer and Clinical Oncology ·C.K. van Kalken, Jacobus J. M. van der Hoeven, Jan de Jong, Giuseppe Giaccone, (unknown), Paul A. Maessen, (unknown), (unknown), (unknown)	27
15	Differential sensitivity of multi‐drug‐resistant and ‐sensitive cells to resistance‐modifying agents and the relation with reversal of anthracycline resistance 1990 ·International Journal of Cancer ·Gerrit Jan Schuurhuis, Herbert M. Pinedo, Henricus J. Broxterman, C.K. van Kalken, Catharina M. Kuiper, Jan Lankelma	17
16	Distribution of multi-drug resistance-associated P-glycoprotein in normal and neoplastic human tissues 1990 ·Annals of Oncology ·Paul van der Valk, C.K. van Kalken, Henk A. M. Ketelaars, HJ Broxterman, George L. Scheffer, C.M. Kuiper, T Tsuruo, J. Lankelma, Coby Meijer, Herbert M. Pinedo, (unknown)	211
17	Pharmacokinetics of trimazosin and its effects on blood pressure, renal function and proteinuria during short-term therapy of patients with impaired renal function and hypertension 1986 ·European Journal of Clinical Pharmacology ·C.K. van Kalken, Jan van der Meulen, P. L. Oe, R. Vriesendorp, A. J. M. Donker	2

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact